$MBIO
MUSTANG BIO, INC. Stock $mbio

$mbio Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-Q Financial Statement

#000114420419025065 Filed on May 10, 2019

Income Statement

Concept	2019 Q1	2018 Q4	2018 Q1
Revenue	$0.00	-$50.00K	$50.00K
YoY Change	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.340M	$1.680M	$2.060M
YoY Change	13.59%	-46.15%	1.48%
% of Gross Profit
Research & Development	$6.960M	$10.22M	$4.292M
YoY Change	62.16%	-18.95%	758.4%
% of Gross Profit
Depreciation & Amortization	$288.0K	$310.0K	$7.000K
YoY Change	4014.29%
% of Gross Profit
Operating Expenses	$9.754M	$11.90M	$6.427M
YoY Change	51.77%	-24.35%	94.4%
Operating Profit	-$9.754M	-$11.85M	-$6.427M
YoY Change	51.77%	-24.67%	94.4%
Interest Expense	$140.0K	$130.0K	$150.0K
YoY Change	-6.67%	0.0%	66.67%
% of Operating Profit
Other Income/Expense, Net	$141.0K	$130.0K	$146.0K
YoY Change	-3.42%	0.78%	65.91%
Pretax Income	-$9.610M	-$11.77M	-$6.280M
YoY Change	53.03%	-24.55%	95.03%
Income Tax
% Of Pretax Income
Net Earnings	-$9.613M	-$11.77M	-$6.281M
YoY Change	53.05%	-24.56%	95.18%
Net Earnings / Revenue			-12562.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$343.8K	-$423.8K	-$238.0K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2018 Q4	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$40.60M	$34.10M	$54.80M
YoY Change	-25.91%	-44.1%	-26.93%
Cash & Equivalents	$36.10M	$16.97M	$18.26M
Short-Term Investments	$5.000M	$17.60M	$37.00M
Other Short-Term Assets	$900.0K	$1.000M	$700.0K
YoY Change	28.57%	233.33%
Inventory
Prepaid Expenses		$1.015M	$666.0K
Receivables
Other Receivables
Total Short-Term Assets	$41.61M	$35.13M	$55.60M
YoY Change	-25.16%	-42.76%	-25.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.864M	$6.858M	$4.400M
YoY Change	56.0%	396.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$261.0K	$271.0K	$594.0K
YoY Change	-56.06%	7.97%
Total Long-Term Assets	$8.873M	$7.629M	$5.500M
YoY Change	61.33%	257.83%
TOTAL ASSETS
Total Short-Term Assets	$41.61M	$35.13M	$55.60M
Total Long-Term Assets	$8.873M	$7.629M	$5.500M
Total Assets	$50.49M	$42.75M	$61.10M
YoY Change	-17.37%	-32.66%	-18.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.300M	$5.600M	$5.300M
YoY Change	37.74%	55.56%	562.5%
Accrued Expenses	$100.0K	$200.0K	$300.0K
YoY Change	-66.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.373M	$5.617M	$5.323M
YoY Change	38.51%	55.55%	556.35%
LONG-TERM LIABILITIES
Long-Term Debt	$12.70M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.900M	$700.0K	$100.0K
YoY Change	1800.0%	600.0%
Total Long-Term Liabilities	$14.60M	$700.0K	$100.0K
YoY Change	14500.0%	600.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.373M	$5.617M	$5.323M
Total Long-Term Liabilities	$14.60M	$700.0K	$100.0K
Total Liabilities	$22.01M	$6.358M	$5.448M
YoY Change	303.95%	73.67%	571.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$88.68M	-$79.07M	-$54.69M
YoY Change	62.16%	63.34%	168.9%
Common Stock	$117.2M	$113.4M	$110.3M
YoY Change	6.19%	14.9%	16.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$28.48M	$36.40M	$55.64M
YoY Change
Total Liabilities & Shareholders Equity	$50.49M	$42.75M	$61.09M
YoY Change	-17.36%	-32.66%	-18.57%

Cashflow Statement

Concept	2019 Q1	2018 Q4	2018 Q1
OPERATING ACTIVITIES
Net Income	-$9.613M	-$11.77M	-$6.281M
YoY Change	53.05%	-24.56%	95.18%
Depreciation, Depletion And Amortization	$288.0K	$310.0K	$7.000K
YoY Change	4014.29%
Cash From Operating Activities	-$6.483M	-$6.520M	-$5.565M
YoY Change	16.5%	26.11%	173.33%
INVESTING ACTIVITIES
Capital Expenditures	$299.0K	-$300.0K	$676.0K
YoY Change	-55.77%	-25.0%
Acquisitions
YoY Change
Other Investing Activities	$12.30M	$5.000M	-$11.08M
YoY Change	-211.01%	-36.14%	2815.79%
Cash From Investing Activities	$12.00M	$4.700M	-$11.75M
YoY Change	-202.13%	-36.83%	3033.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$22.50M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	13.61M	0.000	96.00K
YoY Change	14080.21%		-99.81%
NET CHANGE
Cash From Operating Activities	-6.483M	-6.520M	-5.565M
Cash From Investing Activities	12.00M	4.700M	-11.75M
Cash From Financing Activities	13.61M	0.000	96.00K
Net Change In Cash	19.13M	-1.820M	-17.22M
YoY Change	-211.1%	-180.18%	-136.24%
FREE CASH FLOW
Cash From Operating Activities	-$6.483M	-$6.520M	-$5.565M
Capital Expenditures	$299.0K	-$300.0K	$676.0K
Free Cash Flow	-$6.782M	-$6.220M	-$6.241M
YoY Change	8.67%	30.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	35600000
CY2018Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	16469000
CY2019Q1	us-gaap	Other Short Term Investments OtherShortTermInvestments	5044000
CY2018Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	17604000
CY2019Q1	us-gaap	Other Receivables OtherReceivables	111000
CY2018Q4	us-gaap	Other Receivables OtherReceivables	0
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	857000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1052000
CY2019Q1	us-gaap	Assets Current AssetsCurrent	41612000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	35125000
CY2019Q1	mbio	Property Plant And Equipment Excluding Assets Under Construction PropertyPlantAndEquipmentExcludingAssetsUnderConstruction	6377000
CY2018Q4	mbio	Property Plant And Equipment Excluding Assets Under Construction PropertyPlantAndEquipmentExcludingAssetsUnderConstruction	6465000
CY2019Q1	mbio	Construction In Process Net ConstructionInProcessNet	487000
CY2018Q4	mbio	Construction In Process Net ConstructionInProcessNet	393000
CY2019Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	500000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	500000
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	261000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	271000
CY2019Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6656000
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5381000
CY2019Q1	mbio	Payables And Accruedexpenses Related Parties Current PayablesAndAccruedexpensesRelatedPartiesCurrent	618000
CY2018Q4	mbio	Payables And Accruedexpenses Related Parties Current PayablesAndAccruedexpensesRelatedPartiesCurrent	236000
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7373000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5617000
CY2019Q1	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	0
CY2018Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	741000
CY2019Q1	us-gaap	Liabilities Liabilities	22007000
CY2018Q4	us-gaap	Liabilities Liabilities	6358000
CY2019Q1	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	3000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2019Q1	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	0
CY2018Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	2085000
CY2019Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	117158000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	113378000
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88683000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79070000
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	28478000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	36396000
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50485000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42754000
CY2019Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6960000
CY2018Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4292000
CY2019Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	450000
CY2018Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	75000
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2344000
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2060000
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	9754000
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	6427000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9754000
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6427000
CY2019Q1	us-gaap	Interest Income Other InterestIncomeOther	152000
CY2018Q1	us-gaap	Interest Income Other InterestIncomeOther	146000
CY2019Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	11000
CY2018Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	0
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	141000
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	146000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-9613000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-6281000
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27945802
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26387445
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-6281000
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1995000
CY2018Q1	us-gaap	Depreciation Depreciation	7000
CY2018Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	828000
CY2018Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-787000
CY2018Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	179000
CY2018Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-75000
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5565000
CY2018Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	25000000
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	14000000
CY2018Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	75000
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	676000
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11751000
CY2018Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0
CY2018Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	96000
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	96000
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17220000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35475000
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18255000
CY2018Q1	us-gaap	Interest Paid Net InterestPaidNet	0
CY2018Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2320000
CY2018Q1	mbio	Research Amd Development Licenses Expenditure Incurred But Not Yet Paid ResearchAmdDevelopmentLicensesExpenditureIncurredButNotYetPaid	0
CY2019Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	450000
CY2019Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7784000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7490000
CY2019Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	920000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	632000
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	432000
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1995000
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	3000000
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	5000000
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.57in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s unaudited condensed financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Due to the uncertainty inherent in such estimates actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-9613000
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	432000
CY2019Q1	us-gaap	Depreciation Depreciation	288000
CY2019Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-265000
CY2019Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	111000
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1031000
CY2019Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	382000
CY2019Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6483000
CY2019Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	12500000
CY2019Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	200000
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	299000
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12001000
CY2019Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13613000
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19131000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16969000
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36100000
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	0
CY2019Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	191000
CY2019Q1	us-gaap	Stock Issued1 StockIssued1	2085000
CY2019Q1	mbio	Research Amd Development Licenses Expenditure Incurred But Not Yet Paid ResearchAmdDevelopmentLicensesExpenditureIncurredButNotYetPaid	250000
CY2019Q1	mbio	Potentially Dilutive Securities PotentiallyDilutiveSecurities	8190160
CY2018Q1	mbio	Potentially Dilutive Securities PotentiallyDilutiveSecurities	7203450
CY2019Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27561433
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26610183
CY2019Q1	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	0
CY2018Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	709314
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27561433
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26610183
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1248000
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	99000
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0
CY2019Q1	us-gaap	Notes Payable NotesPayable	12725000
CY2018Q4	us-gaap	Notes Payable NotesPayable	0
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1909000
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	59832000
CY2018Q1	mbio	Stock Issued During Period Value Issued For Founders Agreement StockIssuedDuringPeriodValueIssuedForFoundersAgreement	0
CY2018Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1995000
CY2018Q1	mbio	Share Issued During Period Valueon Exercise Of Warrants ShareIssuedDuringPeriodValueonExerciseOfWarrants	96000
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	55642000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	36396000
CY2019Q1	mbio	Stock Issued During Period Value Issued For Founders Agreement StockIssuedDuringPeriodValueIssuedForFoundersAgreement	0
CY2019Q1	mbio	Stock Issued During Period Value Issued For Equity Fee On Horizon Notes StockIssuedDuringPeriodValueIssuedForEquityFeeOnHorizonNotes	375000
CY2019Q1	mbio	Warrants Issued During Period Value Issued For Horizon Note WarrantsIssuedDuringPeriodValueIssuedForHorizonNote	888000
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	432000
CY2019Q1	mbio	Share Issued During Period Valueon Exercise Of Warrants ShareIssuedDuringPeriodValueonExerciseOfWarrants	0
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	28478000
CY2019Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2020-10-01
CY2019Q1	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.0900
CY2019Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0250
CY2019Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	500000
CY2019Q1	mbio	Percentage Of Prepayment Charge PercentageOfPrepaymentCharge	0.040
CY2019Q1	mbio	Percentage Of Amoritzationloan Date PercentageOfAmoritzationloanDate	0.03
CY2019Q1	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.02
CY2019Q1	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	250000
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	59982
CY2019Q1	us-gaap	Line Of Credit Facility Periodic Payment Principal LineOfCreditFacilityPeriodicPaymentPrincipal	750000
CY2019Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	15000000
CY2017Q4	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	600000
CY2017Q4	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3600000
CY2017Q4	us-gaap	Security Deposit SecurityDeposit	800000
CY2017Q4	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	1300000
CY2019Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	75000
CY2019Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	28000
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	78490000
CY2019Q1	us-gaap	Variable Lease Cost VariableLeaseCost	236537000
CY2019Q1	mbio	Accrued Interest Percentage AccruedInterestPercentage	0.050
CY2019Q1	mbio	Percentage Of Warrant Coverage PercentageOfWarrantCoverage	0.05
CY2019Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.47
CY2019Q1	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	200000
CY2019Q1	us-gaap	Legal Fees LegalFees	30000
CY2019Q1	us-gaap	Line Of Credit Facility Collateral Fees Amount LineOfCreditFacilityCollateralFeesAmount	1200000
CY2019Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1400
CY2019Q1	mbio	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	12000
CY2018Q1	mbio	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	0
CY2019Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	13613000
CY2019Q1	mbio	Issue Of Warrants IssueOfWarrants	888000
CY2018Q1	mbio	Issue Of Warrants IssueOfWarrants	0
CY2018Q1	us-gaap	Stock Issued1 StockIssued1	9558000
CY2019Q1	mbio	Issuance Of Common Shares Equity Fee On Venture Notes IssuanceOfCommonSharesEquityFeeOnVentureNotes	375000
CY2018Q1	mbio	Issuance Of Common Shares Equity Fee On Venture Notes IssuanceOfCommonSharesEquityFeeOnVentureNotes	0
CY2019Q1	mbio	Research And Devlopment License In Accounts Payable And Accrued Expense ResearchAndDevlopmentLicenseInAccountsPayableAndAccruedExpense	450000
CY2018Q1	mbio	Research And Devlopment License In Accounts Payable And Accrued Expense ResearchAndDevlopmentLicenseInAccountsPayableAndAccruedExpense	75000
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2046874
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0896
CY2019Q1	mbio	Lessee Operating Lease Liability Assets Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityAssetsPaymentsRemainderOfFiscalYear	-274568
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	460838
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	467141
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	475506
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	489028
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1458068
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3076013
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1068458
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2007555
CY2019Q1	us-gaap	Assets Assets	50485000
CY2018Q4	us-gaap	Assets Assets	42754000
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6864000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6858000
CY2019Q1	us-gaap	Debt Instrument Description DebtInstrumentDescription	The events of default under the Loan Agreement include, among other things, without limitation, and subject to customary grace periods, (1) the Company's failure to make any payments of principal or interest under the Loan Agreement, promissory notes or other loan documents, (2) the Company's breach or default in the performance of any covenant under the Loan Agreement, (3) the occurrence of a material adverse change, (4) the Company making a false or misleading representation or warranty in any material respect, (5) the Company's insolvency or bankruptcy, (6) certain attachments or judgments on the Company's assets, or (7) the occurrence of any material default under certain agreements or obligations of the Company involving indebtedness in excess of $250,000. If an event of default occurs, Horizon is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement.
CY2019Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	288184
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	MUSTANG BIO, INC.
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001680048
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019Q1	dei	Trading Symbol TradingSymbol	MBIO
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	700000
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1200000
CY2019Q1	mbio	Significant Accounting Policies SignificantAccountingPolicies	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Significant Accounting Policies</div></div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.61in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">There have been no material changes to the Company’s significant accounting policies previously disclosed in the Company’s Form 10-K filed with the SEC on March 18, 2019, with the exception of </div>the adoption of the Financial Accounting Standards Board (FASB) Accounting Standard Updates (ASU) ASU 2016-02, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases, </div>and 2018-07,<div style="font-style:italic;display:inline;;font-style:italic;display:inline;"> Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</div><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1	mbio	Operating Lease Right Of Use Assets Amortization OperatingLeaseRightOfUseAssetsAmortization	30000
CY2018Q1	mbio	Operating Lease Right Of Use Assets Amortization OperatingLeaseRightOfUseAssetsAmortization	0
CY2019Q1	mbio	Fair Value Of Warrant Issued FairValueOfWarrantIssued	900000
CY2019Q1	mbio	Total Lease Expense TotalLeaseExpense	315027000
CY2019Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3500000
CY2019Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	6.42
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	22500000
CY2019Q1	mbio	Annual Fees Expenses On Founders Agreement AnnualFeesExpensesOnFoundersAgreement	400000
CY2019Q1	mbio	Shares Issued During The Period Value Of Shares Classified As Available For Sale SharesIssuedDuringThePeriodValueOfSharesClassifiedAsAvailableForSale	20900000
CY2019Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	15000000
CY2018Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0
CY2019Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2275000
CY2018Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0
CY2019Q1	us-gaap	Notes Payable NotesPayable	12725000
CY2018Q4	us-gaap	Notes Payable NotesPayable	0
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	276000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	460000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	467000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	476000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	489000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1458000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3626000

Files In Submission

Name	View Source	Status
0001144204-19-025065-index-headers.html	Edgar Link	pending
0001144204-19-025065-index.html	Edgar Link	pending
0001144204-19-025065.txt	Edgar Link	pending
0001144204-19-025065-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mbio-20190331.xml	Edgar Link	completed
mbio-20190331.xsd	Edgar Link	pending
mbio-20190331_cal.xml	Edgar Link	unprocessable
mbio-20190331_def.xml	Edgar Link	unprocessable
mbio-20190331_lab.xml	Edgar Link	unprocessable
mbio-20190331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv520179_10q.htm	Edgar Link	pending
tv520179_ex31-1.htm	Edgar Link	pending
tv520179_ex31-2.htm	Edgar Link	pending
tv520179_ex32-1.htm	Edgar Link	pending
tv520179_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MBIO
MUSTANG BIO, INC. Stock $mbio

2019 Q1 Form 10-Q Financial Statement

#000114420419025065 Filed on May 10, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBIO MUSTANG BIO, INC. Stock $mbio

2019 Q1 Form 10-Q Financial Statement

#000114420419025065 Filed on May 10, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBIO
MUSTANG BIO, INC. Stock $mbio